Does a higher LDL particle number and elevated Lp(a) increase atherosclerotic risk?

Low-density lipoprotein particle number (LDL-P) and lipoprotein(a) [Lp(a)] are critical markers of cardiovascular risk that reflect the total concentration of atherogenic particles in circulation. While standard cholesterol measures track the mass of cholesterol, particle counts more accurately reflect the primary drivers of arterial plaque formation.

Mechanisms of Atherogenesis

The risk associated with a high LDL-P is rooted in the subendothelial retention model of atherosclerosis. Every LDL particle contains exactly one molecule of apolipoprotein B (apoB), which acts as the structural "passport" for the particle.

• Particle Flux: The rate at which lipoproteins cross the endothelial barrier and enter the arterial wall is primarily driven by the concentration of circulating apoB-containing particles, rather than their total cholesterol content.
• Intimal Trapping: Once inside the arterial intima, these particles bind to proteoglycans, leading to their retention. This process triggers oxidation, inflammation, and the formation of macrophage foam cells, which are the hallmarks of atherosclerotic plaque.
• Predictive Value: Research from the MESA study and the Women's Health Study indicates that when LDL-P and LDL-C are discordant (e.g., low cholesterol but high particle count), the risk of coronary heart disease aligns more closely with the particle number.

Additive Risk of Lipoprotein(a)

Lp(a) contributes to cardiovascular risk through mechanisms that are independent of, and additive to, the risk posed by LDL-P.

• Particle Burden: Like LDL, each Lp(a) particle contains one molecule of apoB-100. Consequently, elevated Lp(a) increases the total number of atherogenic particles available to enter the arterial wall, a burden often underestimated by standard LDL assays.
• Unique Pathogenicity: Lp(a) carries an additional protein, apolipoprotein(a), which has high structural similarity to plasminogen. This allows it to inhibit fibrinolysis (the breakdown of blood clots), promoting a pro-thrombotic environment.
• Inflammation and Calcification: Lp(a) is the primary carrier of oxidized phospholipids (OxPL) in the blood. These phospholipids drive vascular inflammation and promote the calcification of both the arterial wall and the aortic valve, risk factors that are not addressed by standard LDL-lowering therapies.

Clinical Implications

In clinical practice, identifying individuals with high LDL-P or elevated Lp(a) allows for a more precise assessment of "residual risk"—the risk that remains even after LDL cholesterol is lowered to goal. Large-scale Mendelian randomization studies have confirmed that Lp(a) is a potent, independent risk factor that persists even when LDL-P is well-controlled.

Bottom line

A higher LDL-P increases atherosclerotic risk by providing more apoB-containing particles for arterial entry and retention. Lipoprotein(a) further escalates this risk by adding to the total particle count and introducing unique pro-thrombotic and pro-inflammatory pathways.